



Diabetes does not modify the renal-protective effect of intravenous amino acids infusion after cardiac surgery

Michela Consonni¹ · Stefano Fresilli¹ · Yuki Kotani² · Eugenio Garofalo³ · Nikola Bradic^{4,5} · Anna Mara Scandroglio¹ · Lian Kah Ti⁶ · Marco Comis⁷ · Alessandro Oriani¹ · Antonio Pisano⁸ · Alessandro Belletti¹ · Fabio Guarracino⁹ · Rosario Losiggio^{1,27} · Martina Baiardo Redaelli^{10,11} · Domenico Pontillo¹ · Cristina Arangino¹² · Alessandro Pruna¹ · Francesco Federici¹³ · Filippo D'Amico¹ · Simona Silveti¹⁴ · Rosa Labanca¹ · Federica Ferrod⁷ · Giuseppe Pittella¹⁵ · Federica Corbo¹ · Marco Ranucci¹⁶ · Andrea Cortegiani^{17,18} · Gianluca Paternoster^{19,20} · Tiziana Bove^{21,22} · Federico Longhini³ · Fabrizio Monaco^{23,24} · Alberto Zangrillo^{1,25} · Lorenzo Piemonti^{25,26} · PROTECTION Study Group Collaborators

Received: 21 October 2025 / Accepted: 28 December 2025 / Published online: 9 January 2026
© The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE) 2026

Abstract

Purpose Acute kidney injury (AKI) is a common complication after cardiac surgery and is associated with increased morbidity and mortality. Intravenous amino acids (AA) infusion reduces postoperative AKI. Given the high prevalence of patients with diabetes and their increased susceptibility to renal injury, this study aimed to assess whether the renal-protective effect of AA infusion is maintained in this population.

Methods This post-hoc subgroup analysis examined patients with diabetes included in the multinational, double-blind, randomized, placebo-controlled PROTECTION trial. Participants were randomized to receive a continuous intravenous infusion of AA (2 g/kg of the ideal body weight per day; up to 72 h) or placebo during the perioperative period of cardiac surgery.

Results Among 644 patients with diabetes (AA $n=309$; placebo $n=335$), the incidence of any-stage AKI was 43.3% in the AA group versus 47.8% in the placebo group, with no significant interaction observed compared to patients without diabetes (interaction $p=0.82$). Similarly, stage 3 AKI occurred in 2.3% of patients in AA group versus 4.8% in the placebo group, with no interaction detected (interaction $p=0.65$).

Conclusion The beneficial effect of perioperative AA infusion has similar magnitude and direction among patients with or without diabetes. These findings support the use of AA infusion as a renal-protective strategy for all patients undergoing cardiac surgery.

Trial registration number ClinicalTrials.gov NCT03709264 – registered on October 17th, 2018.

Keywords Acute kidney injury · Amino acids · Anesthesia · Cardiac surgery · Cardiopulmonary bypass · Renal-replacement therapy

Introduction

Diabetes mellitus (DM) is a global epidemic affecting approximately 537 million adults as of 2021 [1]. Among surgical populations, up to 20% of individuals undergoing general surgery have DM,¹ and the prevalence is even higher in cardiac surgery cohorts, with studies reporting up

to 43% of patients undergoing coronary artery bypass grafting (CABG) are affected [1, 2].

Acute kidney injury (AKI) is a frequent and serious complication after cardiac surgery, associated with substantial short- and long-term morbidity and mortality [3]. Among established risk factors, DM plays a central role as an independent determinant of AKI, complicating perioperative

A complete list of PROTECTION Study Group Collaborators is provided in the Supplementary Appendix

Extended author information available on the last page of the article

management of affected patients [4]. Furthermore, the relationship between AKI and DM is bidirectional: AKI is a potential contributor to the development of new-onset DM, creating a self-perpetuating cycle that accelerates progression towards chronic kidney disease (CKD) [5]. The coexistence of preexisting CKD further increases susceptibility to AKI [6]. In this complex clinical context, targeted preventive strategies are essential. A recent large randomized trial (the PROTECTION trial) demonstrated that intravenous amino acids (AA) infusion reduces the incidence of AKI in patients undergoing cardiac surgery [7]. By recruiting the renal functional reserve, AA may preserve kidney function from acute injury [8–12], even in high-risk subgroups [13, 14]. Given the high prevalence of DM in the cardiac surgical population and its strong association with the AKI risk [15], it is important to determine whether the efficacy of AA infusion differs between patients with or without DM.

Accordingly, we conducted a post-hoc analysis of the PROTECTION trial [7] to assess whether the perioperative AA infusion reduces the incidence of AKI after elective cardiac surgery in patients with DM.

Methods

Study design

This post-hoc analysis was conducted within the PROTECTION trial [7], a multinational, randomized, double-blind, placebo-controlled study performed across 22 institutions in different countries [7]. The PROTECTION trial enrolled patients scheduled for elective cardiac surgery with cardiopulmonary bypass (CPB) between October 28, 2019, and January 17, 2024. Details of the trial design and main results have been reported previously [7, 16]. Briefly, 3,511 adult patients meeting the eligibility criteria were randomized to receive a continuous intravenous infusion of either a balanced AA solution (Isopuramin 10%; Baxter, USA) at 2 g/kg of the ideal body weight per day (maximum 100 g/day), or a placebo (Ringer's solution; Baxter) at equivalent volume. The infusion was initiated in the operating room and continued for up to 72 h, until intensive care unit (ICU) discharge, or initiation of renal replacement therapy (RRT), whichever occurred first. The primary endpoint of the original trial was the occurrence of AKI, defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria [17]. Study protocols were approved by the ethics committees of all participating institutions, and all patients provided written informed consent. The trial was supported by the Italian Ministry of Health.

Inclusion and exclusion criteria

Eligible participants were adults (aged ≥ 18 years) undergoing elective cardiac surgery requiring CPB and a planned postoperative ICU stay of at least one night. Key exclusion criteria included ongoing or planned RRT and advanced CKD (estimated glomerular filtration rate [GFR] < 30 mL/min/1.73 m²). For this post-hoc analysis, we included patients with pre-existing DM, defined as active treatment with insulin or glucose-lowering agents prior to surgery.

Outcomes

The primary endpoint was to compare AKI within 7 days after randomization (according to the KDIGO serum creatinine criteria [17]) in patients with or without DM. Baseline creatinine was defined as the most recent value obtained prior to randomization, either during hospital admission or within the previous 12 months. Secondary outcomes included the highest AKI stage, need for and duration of RRT, length of stay in ICU and hospital, duration of mechanical ventilation, and all-cause mortality at predefined time points. Interaction analyses were performed to evaluate the treatment effects (AA vs. placebo) stratified by DM status.

Statistical analysis

Categorical variables were reported as absolute frequencies and percentages and compared using chi-square or Fisher's exact tests, as appropriate. Continuous variables were expressed as mean $\pm$ standard deviation (SD) or median with interquartile range (IQR) and compared using t-test or Wilcoxon–Mann–Whitney test, as appropriate. Between-group differences in both primary and secondary outcomes were expressed as relative risks (RRs) for binary outcomes, and mean differences (MDs) for continuous variables, with corresponding 95% confidence intervals (CIs). A sensitivity analysis was performed among patients with DM receiving insulin therapy at baseline.

Subgroup analyses were performed according to sex, age, New York Heart Association (NYHA) heart failure class, and baseline eGFR. Interaction terms were reported as RRs with 95% CIs. Time-to-event analyses for any-stage AKI, and RRT initiation were performed using the Fine and Gray competing risk model, with death within the first 7 days treated as a competing event. Gray's test was used to compare cumulative incidence of functions, reporting sub-distribution hazard ratios (SHRs) with 95% CIs.

Bayesian analysis of the primary outcome was also performed using a semi-informative prior derived from a recent meta-analysis [18] (excluding the PROTECTION trial to

prevent double counting), combined with a non-informative component on the log-RR scale. Event counts were modelled using binomial likelihoods, and 100,000 Monte Carlo simulations were used to generate the posterior RR distribution. We report the posterior probability of benefit ($\text{Pr}[\text{RR} < 1]$) and the corresponding 95% credible interval.

All analyses were two-sided, with $p < 0.05$ considered statistically significant. Statistical analyses were performed using Stata version 18 (StataCorp, USA), R-software version 4.4.1 (R Foundation for Statistical Computing, Vienna), and SAS version 9.4 (SAS Institute, USA).

Results

Characteristics of the study population

Among the 3,511 patients enrolled in the PROTECTION trial, 644 (18.3%) had preexisting DM treated with medical therapy at the time of randomization. Of these, 309 were assigned to the AA group and 335 to the placebo group. Within this cohort with DM, 118 patients in the AA group and 122 in the placebo group were receiving insulin therapy at baseline (Fig. 1). Baseline demographic and intraoperative characteristics were well balanced between AA and placebo groups (Table 1 and Suppl. Table S1). Overall, 69% of patients with DM underwent CABG.

Fig. 1 Flow diagram of patient selection. AA denotes amino acids




Table 1 Baseline and intraoperative characteristics of patients with diabetes at randomization

	Amino Acids <i>N</i> =309	Placebo <i>N</i> =335
Median age (IQR) — yr	68 (62–73)	69 (64–74)
Female sex — no. (%)	82 (26.5)	84 (25.1)
Median body-mass index (IQR) [†]	27.4 (24.5–30.1)	27.3 (24.6–30.8)
Median preoperative serum creatinine (IQR) — mg/dl	1.00 (0.83–1.20)	0.96 (0.81–1.18)
Median preoperative hemoglobin concentration (IQR) — g/dl	13.3 (11.8–14.3)	13.0 (11.8–14.3)
Median left ventricular ejection fraction (IQR) — %	55 (45–60)	55 (50–60)
New York Heart Association class — no. (%)		
I	47 (15.2)	59 (17.6)
II	149 (48.2)	164 (49.0)
III	96 (31.1)	104 (31.0)
IV	16 (5.2)	8 (2.4)
Current smoker — no. (%)	67 (21.7)	64 (19.1)
Race or ethnic group — no. (%)		
White	298 (96.4)	323 (96.4)
Asian	6 (1.9)	7 (2.1)
Other	5 (1.6)	5 (1.5)
Medical condition — no. (%)		
Arterial hypertension on medical treatment	262 (84.8)	289 (86.3)
Previous myocardial infarction	99 (32.0)	96 (28.7)
Atrial fibrillation	54 (17.5)	52 (15.5)
Previous stroke or transient ischemic attack	22 (7.1)	32 (9.6)
Cardiac catheterization in the past 48 h	39 (12.6)	42 (12.5)
Peripheral vascular disease	93 (30.1)	140 (41.8)
Previous cardiac surgery	14 (4.5)	13 (3.9)
Preoperative medical therapy — no. (%)		
Statin	214 (69.3)	239 (71.3)
Antiplatelet	205 (66.3)	216 (64.5)
Beta blockers	186 (60.2)	212 (63.3)
ACE inhibitor or ARB	193 (62.5)	203 (60.6)
Diuretics	143 (46.3)	150 (44.8)
Anticoagulant	66 (21.4)	91 (27.2)
Median duration of on-pump procedure (IQR) — min	92 (75–118)	97 (76–123)
Surgery type — no. (%)		
CABG	210 (68.0)	231 (69.0)
Aortic valve	100 (32.4)	118 (35.2)
Mitral valve	61 (19.7)	66 (19.7)
Other	11 (3.6)	8 (2.4)
Intraoperative loop diuretics — no. (%)	105 (34.0)	112 (33.4)
Use of hemofiltration during CPB — no. (%)	14 (4.5)	29 (8.7)
Intraoperative vasoactive and inotropic drugs — no. (%)		
Norepinephrine	213 (68.9)	208 (62.1)
Epinephrine	113 (36.6)	125 (37.3)
Dobutamine	77 (24.9)	67 (20.0)
Other	41 (13.3)	51 (15.2)
	14 (4.5)	13 (3.9)

*To convert serum creatinine to millimoles per liter, multiply by 88.4. Percentages may not total 100 because of rounding. ACE denotes angiotensin converting enzyme; ARB angiotensin receptor blocker; CABG coronary artery bypass graft; CPB cardiopulmonary bypass; IQR interquartile range. NYHA: New York Heart Association class for heart failure (range I–IV, class I is a patient asymptomatic for heart failure, class IV is a patient with symptoms of heart failure at rest). [†]The body-mass index is the weight in kilograms divided by the square of the height in meters.

Primary outcomes

The renal-protective effect of AA infusion on AKI was consistent across patients with and without DM, with no evidence of interaction (interaction $p=0.82$) (Fig. 2). Among patients with DM, the incidence of any-stage AKI was 43.3% in the AA group versus 47.8% in the placebo group (RR 0.91, 95% CI 0.77 to 1.08, $p=0.26$) (Table 2) (Suppl.

Figure S1). In the Bayesian analysis, the posterior probability of any benefit (RR < 1) was 97.5%, indicating that, given prior evidence and the current data, there is a 97.5% probability that AA infusion truly reduces AKI incidence rather than increases it (Fig. 3).

Findings were confirmed in a sensitivity analysis limited to patients with DM receiving insulin therapy at baseline (Suppl. Figure S2) (Suppl. Table S2).




Fig. 2 Subgroup analyses for any stage acute kidney injury (AKI), stage 3 AKI, and need for renal replacement therapy according to diabetes status. RR denotes relative risk, CI confidence interval

Table 2 Primary and secondary outcomes in patients with baseline diabetes requiring medical treatment

	Amino acids (<i>n</i> =309)		Placebo (<i>n</i> =335)		Relative risk, absolute mean difference (95% CI)	<i>p</i> value
	Value	No. with missing data	Value	No. with missing data		
Primary outcome						
Incidence of in-hospital AKI † — no. (%)	133 (43.3)	2	160 (47.8)	0	0.91 (0.77 to 1.08)	0.26
Stage 1 AKI	120 (39.1)	2	138 (41.2)	0	0.95 (0.79 to 1.15)	0.59
Stage 2 AKI	6 (1.9)	2	6 (1.8)	0	1.09 (0.36 to 3.35)	0.88
Stage 3 AKI	7 (2.3)	2	16 (4.8)	0	0.48 (0.20 to 1.14)	0.089
Secondary outcomes						
Use of renal-replacement therapy — no. (%)	6 (2.0)	4	12 (3.6)	1	0.55 (0.21 to 1.44)	0.22
Renal-replacement therapy duration (IQR) — hours	35 (12 to 89)	0	45 (14 to 80)	1	-52.73 (-171.60 to 66.10) [‡]	0.35
Mechanical ventilation duration (IQR) — hours	12 (5 to 17)	14	10 (4 to 16)	14	2.52 (-7.02 to 12.07) [‡]	0.60
Length of stay in intensive care unit (IQR) – hours	43 (22 to 74)	10	44 (22 to 71)	5	-1.08 (-18.77 to 16.61) [‡]	0.90
Length of stay in hospital (IQR) — days	7 (6 to 11)	2	7 (6 to 11)	0	0.26 (-1.33 to 1.86) [‡]	0.74
Mortality in intensive care unit — no. (%)	12 (3.9)	1	13 (3.9)	0	1.00 (0.47 to 2.17)	0.99
Mortality at 30 days — no. (%)	17 (5.5)	1	17 (5.1)	0	1.09 (0.57 to 2.09)	0.80
Mortality at 90 days — no. (%)	18 (6.0)	7	18 (5.4)	3	1.10 (0.58 to 2.07)	0.77
Mortality at 180 days — no. (%)	21 (7.0)	10	20 (6.1)	5	1.16 (0.64 to 2.09)	0.63

*Data are presented as relative risks for dichotomous outcomes and as absolute mean differences for continuous outcomes. AKI denotes acute kidney injury; CI confidence interval; IQR interquartile range. †Acute kidney injury is defined according to KDIGO 2012 guidelines.[‡]Data presented as absolute mean difference




Fig. 3 Bayesian posterior probability distribution for acute kidney injury (AKI) comparing amino acid infusion with placebo. The shaded area represents the posterior probability of benefit ($RR < 1$)

Subgroup analyses showed no statistically significant differences across gender, age, baseline eGFR, or NYHA functional class (Suppl. Figure S3).

Secondary outcomes

The incidence of stage 3 AKI was 2.3% in the AA group vs. 4.8% in the placebo group (Suppl. Figure S4), with no evidence of interaction (interaction $p=0.65$) (Fig. 2). Similarly, 6 patients (2.0%) in the AA group vs. 12 (3.6%) in the placebo group required RRT (interaction $p=0.47$) (Fig. 2) (Suppl. Figures S5). No significant between-group differences were observed in other secondary outcomes, including duration of RRT, duration of mechanical ventilation, ICU stay, hospital stay, or all-cause mortality at any time point (Table 2). Sensitivity analyses limited to patients with DM receiving insulin therapy at baseline yielded consistent results across all secondary outcomes (Suppl. Table S2) (Suppl. Figures S6 and S7).

Discussion

Key findings

In this subgroup analysis of the PROTECTION trial, we evaluated the efficacy of perioperative intravenous AA infusion in 644 patients with DM undergoing cardiac surgery. The effect of AA on the prevention of postoperative AKI among patients with DM was consistent in both magnitude and direction with that observed in patients without DM, with no evidence of effect modification by DM status (interaction p -value=0.82). Similar findings were obtained when stratifying by baseline insulin therapy, and results remained robust across multiple sensitivity analyses.

As expected, the incidence of AKI was significantly higher in patients with DM (>40%) compared to the overall PROTECTION cohort ($\approx 30\%$). The most severe outcome, stage 3 AKI, showed a marked numerical reduction in the diabetic subgroup: it was halved in the AA group (2.3%) compared to the placebo group (4.8%). The magnitude of the observed effect suggests consistency with the established renal-protective properties of AA, which were shown

to reduce the incidence of AKI in the overall PROTECTION trial population.

Relationship to previous studies

DM is a well-established risk factor for both microvascular and macrovascular disease, markedly increasing susceptibility to renal injury [19, 20]. Structural and functional changes in the diabetic kidney, such as glomerular hypertrophy, basement-membrane thickening, and interstitial fibrosis, contribute to impaired renal perfusion and filtration, predisposing patients to AKI during hemodynamic stress, such as cardiac surgery [19]. Importantly, intraoperative hemodynamic instability further amplifies this risk [21–23].

In our cohort, CABG was the most common procedure, consistent with the high prevalence of coronary artery disease in patients with DM [24]. Previous studies reported an increased incidence of AKI after CABG in this population [25–28] and similar findings have been described for other cardiovascular interventions, such as transcatheter aortic valve replacement [29].

Despite this recognized vulnerability, no prior studies have specifically evaluated the effect of AA infusion in patients with DM undergoing cardiac surgery. Experimental and clinical evidence, however, suggests that specific AA may confer renal protection through anti-inflammatory, antioxidant, and metabolic pathways. Histidine has been reported to reduce oxidative stress and inflammation [30, 31], tryptophan [30, 32, 33] and glutamine [30, 34] may modulate glucose metabolism and renal function through GLP-1-related pathways, while the role of branched-chain AA (BCAAs) remains debated [30]. Although heterogeneous, these data provide a plausible biological rationale for AA-mediated nephroprotection in DM. Our findings confirm that the clinical and economic [35] benefit observed in the overall PROTECTION population extends to patients with DM, independent of baseline antidiabetic therapy.

Implications of study findings

Understanding the role of DM in the context of AA-mediated renal protection may support the development of personalized preventive strategies for cardiac surgical patients at increased risk of AKI. In clinical practice, recognizing DM as a major risk factor and tailoring perioperative nephroprotection, including AA infusion, may help improve outcomes, optimize ICU resources use, and mitigate the long-term burden of AKI and CKD in this growing patient population. Mechanistic studies are warranted to clarify how renal functional reserve progressively declines as DM advances.

Strengths and limitations

Strengths of this analysis include its basis in a large, randomized, double-blind, placebo-controlled trial; the rigorous outcomes definition according to KDIGO criteria; and the availability of details subgroup data, including analyses stratified by insulin use and sensitivity testing. Nonetheless, several limitations should be acknowledged. First, this was a post-hoc exploratory analysis not powered for subgroup comparisons, which increases the risk of type II error. Second, the definition of DM was based on treatment status rather than metabolic parameters, with no data on disease duration, HbA1c, or the presence of micro- and macrovascular complications. Finally, these results may not be applied to patients undergoing off-pump or urgent cardiac surgery.

Future perspectives

Future studies should incorporate detailed metabolic and renal phenotyping. The integration of early renal biomarkers (e.g., NGAL, KIM-1, cystatin C) could enhance risk stratification and enable earlier detection of AKI in high-risk individuals. Long-term follow-up is needed to determine whether AA infusion influences CKD progression or cardiovascular outcomes in patients with DM. Ultimately, perioperative strategies that combine metabolic, nutritional, and pharmacological interventions could lead to more personalized and effective approaches for AKI prevention.

Conclusions

In this subgroup analysis of the PROTECTION trial, perioperative intravenous AA infusion was associated with a consistent reduction in postoperative AKI among patients with and without DM undergoing cardiac surgery. Despite their higher baseline risk of renal complications, patients with DM had similar benefits from AA infusion. These findings support the use of AA infusion as a preventive strategy in high-risk surgical populations and underscore the need for prospective trials specifically designed to confirm these results in cohorts with DM.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40618-025-02804-0>.

Acknowledgements None.

Authors contributions Conceptualization: M. Consonni, S. Fresilli, Y. Kotani, A. Belletti, R. Losiggio, M. Baiardo Redaelli, A. Zangrillo, L. Piemonti; Data curation: M. Consonni, E. Garofalo, N. Bradic, A.M. Scandroglio, L.K. Ti, M. Comis, A. Oriani, A. Pisano, F. Guar-

racino, R. Losiggio, D. Pontillo, C. Arangino, A. Pruna, F. Federici, F. D'Amico, S. Silvetti, R. Labanca, F. Ferrod, G. Pittella, F. Corbo, M. Ranucci, A. Cortegiani, G. Paternoster, T. Bove, F. Longhini, F. Monaco; Formal analysis: S. Fresilli, Y. Kotani, R. Losiggio, D. Pontillo; Funding acquisition: A. Zangrillo. Investigation: M. Consonni, S. Fresilli, Y. Kotani, E. Garofalo, N. Bradic, A.M. Scandroglio, L.K. Ti, M. Comis, F. D'Amico, S. Silvetti, R. Labanca, F. Ferrod, G. Pittella, F. Corbo, M. Ranucci, A. Cortegiani; Methodology: A. Oriani, A. Belletti, F. Guarracino, R. Losiggio, M. Baiardo Redaelli, D. Pontillo, C. Arangino, A. Pruna, F. Federici, G. Paternoster, T. Bove, F. Longhini, F. Monaco, A. Zangrillo, L. Piemonti; Project administration: A. Cortegiani, G. Paternoster, T. Bove, F. Longhini, F. Monaco, A. Zangrillo, L. Piemonti. Resources: M. Consonni, S. Fresilli, Y. Kotani, R. Losiggio; Software: E. Garofalo, N. Bradic, A.M. Scandroglio, L.K. Ti, M. Comis, A. Oriani, A. Belletti, F. Guarracino, M. Baiardo Redaelli, D. Pontillo, C. Arangino, A. Pruna, F. Federici, F. D'Amico, S. Silvetti, R. Labanca, F. Ferrod, G. Pittella, F. Corbo, M. Ranucci, A. Cortegiani, G. Paternoster, T. Bove, F. Longhini, F. Monaco, A. Zangrillo; Have read and agreed to the published version of the manuscript and can attest to the validity of the work: all authors.

Funding The PROTECTION trial was supported by a grant from the Italian Ministry of Health (RF-2016-02363260).

Declarations

Competing interests The authors declare that they have no conflict of interest.

References

- American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2025. *Diabetes Care* (2025); 48(1 Suppl 1):S321–S334. <https://doi.org/10.2337/DC25-S016>
- Brush JE, Siraj ES, Kemp CD et al (2019) Effect of diabetes mellitus on complication rates of coronary artery bypass grafting. *Am J Cardiol* 124(9):1389–1396. <https://doi.org/10.1016/j.amjcard.2019.07.053>
- Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ (2021) Acute kidney injury. *Nat Reviews Disease Primers* 7(1):52. <https://doi.org/10.1038/S41572-021-00284-Z>
- National Diabetes Statistics Report | Diabetes | CDC. Center for Disease Control. May 15 (2024) Accessed October 4, 2025. <https://www.cdc.gov/diabetes/php/data-research/index.html>
- Lin YF, Lin SL, Huang TM et al (2018) New-Onset diabetes after acute kidney injury requiring Dialysis. *Diabetes Care* 41(10):2105–2110. <https://doi.org/10.2337/DC17-2409>
- Baiardo Redaelli M, Monaco F, Bradic N et al (2025) Amino acid infusion for kidney protection in cardiac surgery patients with chronic kidney disease: A secondary analysis of the PROTECTION trial. *Anesthesiology* 142(5):818–828. <https://doi.org/10.1097/ALN.0000000000005336>
- Landoni G, Monaco F, Ti LK et al (2024) A randomized trial of intravenous amino acids for kidney protection. *N Engl J Med* 391(8):687–698. <https://doi.org/10.1056/NEJMOA2403769>
- Losiggio R, Baiardo Redaelli M, Landoni G, Bellomo R (2025) Intravenous Amino-acid infusion to prevent acute kidney injury after cardiac surgery: A review of the evidence. *Ann Thorac Surg* 120(2):256–266. <https://doi.org/10.1016/j.athoracsur.2024.11.020>
- Losiggio R, Baiardo Redaelli M, Landoni G, Bellomo R (2025) Amino acid infusion and renal protection: beyond hemodynamic optimization in cardiac surgery. *Ann Thorac Surg* 120(3):614–615. <https://doi.org/10.1016/j.athoracsur.2025.03.019>
- Losiggio R, Baiardo Redaelli M, Pruna A, Landoni G, Bellomo R (2024) The renal effects of amino acids infusion. *Signa Vitae* 20(7):1–4. <https://doi.org/10.22514/sv.2024.079>
- Kotani Y, Baiardo Redaelli M, Pruna A et al (2024) Intravenous amino acid for kidney protection: current Understanding and future perspectives. *Clin Kidney J* 18(2):sfac409. <https://doi.org/10.1093/CKJ/SFAE409>
- Jufar AH, Lankadeva YR, May CN, Cochrane AD, Bellomo R, Evans RG (2020) Renal functional reserve: from physiological phenomenon to clinical biomarker and beyond. *Am J Physiol Regul Integr Comp Physiol* 319(6):R690–R702. <https://doi.org/10.1152/AJPREGU.00237.2020>
- Belletti A, Pisano A, Scandroglio AM et al (2025) Intravenous amino acids for renal protection in patients receiving temporary mechanical circulatory support: a secondary subgroup analysis of the PROTECTION study. *Eur J Cardiothorac Surg* 67(2):ezaf035. <https://doi.org/10.1093/EJCTS/EZAF035>
- Pontillo D, Rong LQ, Pruna A et al (2025) Impact of cardiopulmonary bypass duration on the renal effects of amino acids infusion in cardiac surgery patients. *J Cardiothorac Vasc Anesth* 39(9):2296–2306. <https://doi.org/10.1053/j.jvca.2025.05.050>
- Mo M, Huang Z, Gao T et al (2022) Development and validation of short-term renal prognosis prediction model in diabetic patients with acute kidney injury. *Diabetol Metab Syndr* 14(1):197. <https://doi.org/10.1186/S13098-022-00971-1>
- Landoni G, Brambillasca C, Baiardo Redaelli M et al (2022) Intravenous amino acid therapy for kidney protection in cardiac surgery a protocol for a multi-Centre randomized blinded placebo controlled clinical trial. The PROTECTION trial. *Contemp Clin Trials* 121:106898. <https://doi.org/10.1016/j.cct.2022.106898>
- Kellum JA, Lameire N, Aspelin P et al (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 17(1):204. <https://doi.org/10.1186/CC11454>
- Pruna A, Losiggio R, Landoni G et al (2024) Amino acid infusion for perioperative functional renal protection: A Meta-analysis. *J Cardiothorac Vasc Anesth* 38(12):3076–3085. <https://doi.org/10.1053/J.JVCA.2024.08.033>
- Duran-Salgado MB, Rubio-Guerra AF (2014) Diabetic nephropathy and inflammation. *World J Diabetes* 5(3):393–398. <https://doi.org/10.4239/WJD.V5.I3.393>
- Yu SMW, Bonventre JV (2018) Acute kidney injury and progression of diabetic kidney disease. *Adv Chronic Kidney Dis* 25(2):166–180. <https://doi.org/10.1053/j.ackd.2017.12.005>
- Cheruku SR, Raphael J, Neyra JA, Fox AA (2023) Acute kidney injury after cardiac surgery: Prediction, Prevention, and management. *Anesthesiology* 139(6):880–898. <https://doi.org/10.1097/ALN.0000000000004734>
- Wang Y, Bellomo R (2017) Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. *Nat Rev Nephrol* 13(11):697–711. <https://doi.org/10.1038/NRNEPH.2017.119>
- Peng K, McIlroy DR, Bollen BA et al (2022) Society of cardiovascular anesthesiologists clinical practice update for management of acute kidney injury associated with cardiac surgery. *Anesth Analg* 135(4):744–756. <https://doi.org/10.1213/ANE.0000000000006068>

24. Moschopoulou M, Ampatzidou FC, Loutradis C et al (2016) Diabetes mellitus does not affect the incidence of acute kidney injury after cardiac surgery; a nested case-control study. *J Nephrol* 29(6):835–845. <https://doi.org/10.1007/S40620-016-0281-X>
25. Hertzberg D, Sartipy U, Holzmänn MJ (2015) Type 1 and type 2 diabetes mellitus and risk of acute kidney injury after coronary artery bypass grafting. *Am Heart J* 170(5):895–902. <https://doi.org/10.1016/j.ahj.2015.08.013>
26. Arbel Y, Fuster V, Baber U, Hamza TH, Siami FS, Farkouh ME (2019) Incidence, determinants and impact of acute kidney injury in patients with diabetes mellitus and multivessel disease undergoing coronary revascularization: results from the FREEDOM trial. *Int J Cardiol* 293:197–202. <https://doi.org/10.1016/j.ijcard.2019.05.064>
27. Shen R, Wang Y, Zhang B, Ge J (2022) The impact of diabetes on acute kidney injury after Off-Pump coronary artery bypass grafting. *Heart Surg Forum* 25(5):E660–E664. <https://doi.org/10.1532/HSF.4885>
28. Wang R, Zhang H, Zhu Y, Chen W, Chen X (2020) The impact of diabetes mellitus on acute kidney injury after coronary artery bypass grafting. *J Cardiothorac Surg* 15(1):289. <https://doi.org/10.1186/S13019-020-01312-X>
29. Mina GS, Gill P, Soliman D, Reddy P, Dominic P (2017) Diabetes mellitus is associated with increased acute kidney injury and 1-year mortality after transcatheter aortic valve replacement: A meta-analysis. *Clin Cardiol* 40(9):726–731. <https://doi.org/10.1002/CLC.22723>
30. Liu L, Xu J, Zhang Z et al (2022) Metabolic homeostasis of amino acids and diabetic kidney disease. *Nutrients* 15(1):184. <https://doi.org/10.3390/NU15010184>
31. American Diabetes Association (2022) Introduction: standards of medical care in Diabetes-2022. *Diabetes Care* 45(Suppl 1):S1–S2. <https://doi.org/10.2337/DC22-SINT>
32. Agus A, Planchais J, Sokol H (2018) Gut microbiota regulation of Tryptophan metabolism in health and disease. *Cell Host Microbe* 23(6):716–724. <https://doi.org/10.1016/j.chom.2018.05.003>
33. Roager HM, Licht TR (2018) Microbial Tryptophan catabolites in health and disease. *Nat Commun* 9(1):3294. <https://doi.org/10.1038/S41467-018-05470-4>
34. Samocha-Bonet D, Chisholm DJ, Gribble FM et al (2014) Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients—a randomized study. *PLoS ONE* 9(11):e113366. <https://doi.org/10.1371/JOURNAL.PONE.0113366>
35. Carrandi A, Faggery DM, Losiggio R et al (2025) Postoperative cost-effectiveness of prophylactic amino acid therapy for renal protection: A modelled economic evaluation. *J Cardiothorac Vasc Anesth*. Published online August 2025. <https://doi.org/10.1053/jjvca.2025.08.042>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Michela Consonni¹ · Stefano Fresilli¹ · Yuki Kotani² · Eugenio Garofalo³ · Nikola Bradic^{4,5} · Anna Mara Scandroglio¹ · Lian Kah Ti⁶ · Marco Comis⁷ · Alessandro Oriani¹ · Antonio Pisano⁸ · Alessandro Belletti¹ · Fabio Guarracino⁹ · Rosario Losiggio^{1,27}  · Martina Baiardo Redaelli^{10,11} · Domenico Pontillo¹ · Cristina Arangino¹² · Alessandro Pruna¹ · Francesco Federici¹³ · Filippo D'Amico¹ · Simona Silveti¹⁴ · Rosa Labanca¹ · Federica Ferrod⁷ · Giuseppe Pittella¹⁵ · Federica Corbo¹ · Marco Ranucci¹⁶ · Andrea Cortegiani^{17,18} · Gianluca Paternoster^{19,20} · Tiziana Bove^{21,22} · Federico Longhini³ · Fabrizio Monaco^{23,24} · Alberto Zangrillo^{1,25} · Lorenzo Piemonti^{25,26} · PROTECTION Study Group Collaborators

✉ Rosario Losiggio
losiggio.rosario@hsr.it

¹ Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

² Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan

³ Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy

⁴ Clinic of Anesthesiology, Resuscitation and Intensive Care, University Hospital Dubrava, Zagreb, Croatia

⁵ Department of Nursing, University North, Varazdin, Croatia

⁶ Department of Anaesthesia, National University Hospital, Lower Kent Ridge Road, Singapore

⁷ S.C. Anestesia e Rianimazione Cardiovascolare, A.O. Ordine Mauriziano, Umberto I di Torino, Turin, Italy

⁸ Cardiac Anesthesia and ICU, AORN “Dei Colli”, Monaldi Hospital, Naples, Italy

⁹ Department of Cardiothoracic Anaesthesia and IC, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

¹⁰ General and Neurosurgical Intensive Care Units, ASST Sette Laghi, Ospedale Di Circolo, Varese, Italy

¹¹ Department of Biotechnologies and Life Sciences, University of Insubria, Varese, Italy

¹² Department of Cardiothoracic Anesthesia and Intensive Care, IRCCS Centro Cardiologico Monzino, Milan, Italy

¹³ UOC Anestesia e Rianimazione, Azienda Ospedaliero-Universitaria Sant'Andrea, Rome, Italy

¹⁴ Department of Cardiac Anesthesia and Intensive Care, Ospedale Policlinico San Martino IRCCS, IRCCS Cardiovascular Network, Genova, Italy

- ¹⁵ Cardiovascular Anaesthesia and ICU, San Carlo Hospital, Potenza, Italy
- ¹⁶ Department of Cardiovascular Anesthesia and Intensive Care, IRCCS Policlinico San Donato, San Donato Milanese, Italy
- ¹⁷ Department of Precision Medicine in Medical, Surgical and Critical Care Area (Me.Pre.C.C.), University of Palermo, Palermo, Italy
- ¹⁸ Department of Anesthesia, Intensive Care and Emergency, University Hospital Policlinico Paolo Giaccone, Analgesia, Palermo, Italy
- ¹⁹ Department of Health Sciences, University of Basilicata, Potenza, Italy
- ²⁰ Anesthesia and ICU, San Carlo Hospital, Potenza, Italy
- ²¹ Department of Basic Biotechnological Sciences, Intensive Care Peri- Operative Clinics, Università Cattolica del Sacro Cuore, Rome, Italy
- ²² Department of Emergency, Anesthesiological and Reanimation Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- ²³ Departement. of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - University of Bologna, Bologna, Italy
- ²⁴ Cardiothoracic and Vascular Anesthesia and Intensive Care, IRCCS Azienda Ospedaliero-Universitaria Sant'Orsola, Bologna, Italy
- ²⁵ School of Medicine, Vita-Salute San Raffaele University, Milan, Italy
- ²⁶ Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
- ²⁷ Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, Milan 20132, Italy